Gyre Therapeutics (formerly Catalyst Biosciences)
Gyre Therapeutics (formerly Catalyst Biosciences) works on 2 rare diseases tracked on Trial Friend, including Hemophilia A, Hemophilia B.
Gyre Therapeutics, formerly Catalyst Biosciences, completed a business combination in October 2023 and now operates as a biopharmaceutical company focused on fibrotic and inflammatory diseases. The company develops therapies for liver fibrosis and other fibrotic conditions. Gyre completed its all-stock acquisition of Cullgen Inc., valued at approximately $300 million, on May 4, 2026, adding a targeted protein degradation platform. Cullgen CEO Ying Luo became Gyre's president and CEO.
Focus areas at Gyre Therapeutics (formerly Catalyst Biosciences)
Within its broader pharmaceutical portfolio, Gyre Therapeutics (formerly Catalyst Biosciences) has active clinical trial programs and drug development efforts across 2 rare diseases, including Hemophilia A, Hemophilia B. These programs may span orphan drug designation, novel therapeutic mechanisms, and precision medicine approaches targeting the underlying causes of each disease.
The clinical trials section below shows all active and recruiting studies sponsored by Gyre Therapeutics (formerly Catalyst Biosciences), sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites. The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Gyre Therapeutics (formerly Catalyst Biosciences) is headquartered in South San Francisco, United States, founded in 2002, publicly traded under the ticker symbol GYRE. The company maintains a dedicated rare disease division alongside its broader therapeutic portfolio, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Active Clinical Trials
FDA-Approved Drugs
Rare Disease Focus Areas (2)
Diseases targeted by Gyre Therapeutics (formerly Catalyst Biosciences)'s clinical trial and drug development programs
Hemophilia A is an X-linked bleeding disorder caused by deficiency or dysfunction of clotting factor VIII. Severity depends on factor levels, ranging from mild to severe hemorrhage. Modern factor repl...
Hemophilia B is an X-linked bleeding disorder caused by deficiency or dysfunction of clotting factor IX. Clinically indistinguishable from Hemophilia A, the key difference is factor type. Modern facto...
Patient Resources
Organizations and resources related to Gyre Therapeutics (formerly Catalyst Biosciences)'s rare disease focus areas
Frequently Asked Questions About Gyre Therapeutics (formerly Catalyst Biosciences)
Common questions about Gyre Therapeutics (formerly Catalyst Biosciences)'s rare disease programs, clinical trials, and treatments.